Clinical Investigation Unit Trials Currently Recruiting Participants
VBI 2901a CT-01 Trial
The Clinical Investigation unit is currently conducting a clinical trial for a COVID-19 vaccine. The current trial is evaluating the safety and ability of VBI2901a to provoke an immune response. VBI 2901a, a trivalent coronavirus vaccine candidate, is a vaccine targeting 3 Coronavirus diseases: SARS-CoV-1, SARS-CoV-2, as well as MERS. This vaccine is a recombinant ‘spike’ protein with enveloped virus-like particle formulation, and a traditional alum adjuvant, given in one or in two doses. There is no live virus, DNA or RNA component of this vaccine. This vaccine may also provide broader immunity against other related coronaviruses or variants. People who are interested in participating will meet the following criteria:
- Must be between the age of 18-64
- Must be in stable medical condition: Either healthy or with stable health conditions with no changes in the last six months.
- Must have received at least 2 doses of COVID-19 vaccine, the last dose a minimum of 6 months before enrollment.
- Are not pregnant and must be willing to use contraception.
Participants will be given $100 per visit as compensation for their time. The study visit and activity schedule are available upon request.
If you would like to participate or need more information, please contact Bashour Yazji, CIU Clinical Research Coordinator:
Telephone: 613-737-8899, 78811
Fax: 613-737-8696
E-mail: CIU@toh.ca
Principal Investigator: Dr. Bill Cameron
